Disease-specific reference equations for lung function in patients with cystic fibrosis.
American Journal of Respiratory and Critical Care Medicine
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
J. Cyst. Fibros., Aug (2012)
Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Nat. Genet., Aug;44(8):886-9 (2012)
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.
J. Cyst. Fibros., Sep;11(5):446-53 (2012)
Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state.
J. Cyst. Fibros., May;11(3):216-22 (2012)
Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.
Influenza Other Respi Viruses., May;6(3):218-23 (2012)
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Arch Pediatr Adolesc Med., Sep;165(9):847-56 (2011)
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatr. Pulmonol., Feb;47(2):125-34 (2012)
Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
J. Antimicrob. Chemother., Oct;66(10):2398-404 (2011)
Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
Pediatr. Pulmonol., Feb;46(2):184-92 (2011)
An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
Pediatr. Pulmonol., Nov;45(11):1121-34 (2010)
Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
Pediatr. Pulmonol., Sep;45(9):934-44 (2010)
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Pediatr. Pulmonol., Feb;45(2):127-34 (2010)
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Contemp Clin Trials., May;30(3):256-68 (2009)
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
Chest., May;135(5):1223-32 (2009)
Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.
Genet. Med., Dec;10(12):851-68 (2008)
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
J. Pediatr., Feb;154(2):183-8 (2009)
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
Am. J. Respir. Crit. Care Med., Nov;178(9):921-8 (2008)
Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.
Genet. Med., Oct;9(10):695-704 (2007)
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Pediatr. Pulmonol., Jan;43(1):47-58 (2008)